Introduction {#sec1}
============

Late infantile neuronal ceroid lipofuscinosis (LINCL) is an inherited neurodegenerative disease caused by mutations in the gene encoding the lysosomal protease tripeptidyl peptidase 1 (TPP1).[@bib1], [@bib2] Typically, LINCL affects children and results in death in the first or second decade of life. Currently, there is no approved treatment for LINCL.

Enzyme replacement therapy (ERT), where a recombinant form of the protein that is missing or defective is administered to patients, is currently the most effective and widely used therapy for non-neurological forms of lysosomal diseases (reviewed in Hollak and Wijburg[@bib3]). Restoration of TPP1 to the brain of LINCL patients and individuals with related lysosomal diseases is needed to cure the disease. However, the blood-brain barrier (BBB) represents a major obstacle to enzyme delivery. Several clinical trials have taken different approaches to this problem in LINCL, including the use of stem cells (<https://ClinicalTrials.gov>: [NCT00337636](ctgov:NCT00337636){#intref0015}), gene therapy to the parenchyma of the brain (<https://ClinicalTrials.gov>: [NCT00151216](ctgov:NCT00151216){#intref0025}), and cerebrospinal fluid (CSF)-mediated delivery of enzyme via intracerebroventricular (ICV) injection (<https://ClinicalTrials.gov>: [NCT01907087](ctgov:NCT01907087){#intref0035}). Preliminary data appear promising in the latter.[@bib4], [@bib5]

A TPP1-deficient mouse model of LINCL[@bib6] has been used extensively to explore different strategies for treatment, including gene therapy and ERT.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14] The LINCL mouse recapitulates many aspects of the human disease, including progressive locomotor decline (compare [Movies S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc2){ref-type="supplementary-material"}, and [S3](#mmc3){ref-type="supplementary-material"} \[untreated LINCL mice\] with [Movies S4](#mmc4){ref-type="supplementary-material"} and [S5](#mmc5){ref-type="supplementary-material"} \[unaffected wild-type controls\]), and it has a greatly shortened lifespan (∼4--5 months), which allows ready evaluation of the effects of treatment on survival.[@bib6] We have explored several different ERT approaches to delivery of recombinant TPP1 to the brain of the LINCL mouse, potentially to provide rationale for clinical studies. We conducted CSF-mediated administration of TPP1 to the brain by lumbar intrathecal (IT) injection of recombinant protein.[@bib12] This allowed delivery of supraphysiological levels of TPP1 to the brain, and an acute treatment significantly extended the lifespan of the LINCL mice. This treatment also ameliorated cellular pathology and slowed progression of ataxia. In addition, while there is negligible delivery of TPP1 alone to the brain when it is administered intravenously, when co-administered with K16ApoE, a 36-residue peptide containing polylysine and apolipoprotein E sequences, there is robust delivery of TPP1 throughout the brain.[@bib14] As with acute IT administration, intravenous (i.v.) administration of K16ApoE and TPP1 stems neurological symptoms, and acute treatment at 4 weeks of age extends the lifespan of the LINCL mice.

In this study, we have investigated chronic IT ERT in the LINCL mouse, focusing on the effect of timing of treatment initiation on survival and locomotor function. The conclusions drawn from this study may have important translational implications for clinical studies of ERT in LINCL and related disorders.

Results {#sec2}
=======

Chronic IT ERT in Presymptomatic LINCL Mice {#sec2.1}
-------------------------------------------

Acute administration of recombinant human TPP1 (rhTPP1) by IT injection to LINCL mice at 4 weeks of age significantly extended the lifespan of the animals from 16 weeks (vehicle control) to 23 weeks.[@bib12] In this study, one goal was to determine whether chronic administration of rhTPP1 by IT injection could further extend survival. Our experimental plan was to establish cohorts of 13 animals, most of which were allowed to die naturally but sacrificing two at an early 119-day time point (17 weeks) and either the last two to three survivors or all at a predetermined study endpoint of 294 days (42 weeks) for biochemical and histopathological analyses. LINCL mice were dosed with rhTPP1 starting at 6 weeks of age using different treatment regimens and monitored for survival and locomotor function. Median survival of vehicle-treated animals (152 days) was not significantly different from untreated LINCL mice (126 days, [Figure 1](#fig1){ref-type="fig"}A). While premature death was observed in some of the treated animals, a weekly administration of 2.3 mg rhTPP1 ([Figure 1](#fig1){ref-type="fig"}A) significantly (log-rank test p \< 0.0001 and p \< 0.0001 compared to vehicle-treated or untreated, respectively) extended the survival of half of the cohort to more than 300 days (median survival \> 259 days), at which point the study was terminated. It is important to consider the survival data obtained by IT ERT in context with previous studies and these are summarized in [Table 1](#tbl1){ref-type="table"}. There is no significant difference between IT ERT survival data and those obtained from the most effective gene therapy studies to date in the LINCL mouse model (log-rank test p = 0.1001 when compared with treatment at 4 weeks[@bib8] and p = 0.0758 compared with neonatal treatment[@bib15]).

Other doses/dosing regimens extended lifespan of the LINCL animals, but they did not extend survival more than ∼225 days. When LINCL mice were treated with 1 mg rhTPP1 at a weekly dosing interval from 6 weeks of age, survival was significantly (log-rank p \< 0.0001 compared to untreated) extended to a median 220 days ([Figure 1](#fig1){ref-type="fig"}B). Similarly, a biweekly dose of 2.3 mg IT-administered rhTPP1 significantly (log-rank p \< 0.0001 compared to untreated) increased survival of the LINCL mouse ([Figure 1](#fig1){ref-type="fig"}C, median survival 201 days).

Locomotor deficits are a prominent manifestation of LINCL in patients and are present in the LINCL mice[@bib6] (compare [Movies S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc2){ref-type="supplementary-material"}, and [S3](#mmc3){ref-type="supplementary-material"} \[untreated LINCL mice\] with [Movies S4](#mmc4){ref-type="supplementary-material"} and [S5](#mmc5){ref-type="supplementary-material"} \[unaffected wild-type controls\]). Gait analysis[@bib16] is a sensitive measure of locomotor dysfunction in the LINCL mouse[@bib14] that can detect deficits earlier than Rotarod;[@bib6] therefore, we used this approach to evaluate efficacy of chronic IT treatment. In untreated or vehicle-treated animals, stride length started to decline at ∼90 days and decreased precipitously from ∼7 to ∼2 cm until death between 100 and 150 days ([Figure 1](#fig1){ref-type="fig"}A). When mice were treated with IT rhTPP1 in the three survival studies, there was no significant decline in motor function, and, prior to their natural death, animals appeared relatively healthy compared to untreated end-stage LINCL mice ([Figures 1](#fig1){ref-type="fig"}A--1C; compare [Movies S6](#mmc6){ref-type="supplementary-material"} and [S7](#mmc7){ref-type="supplementary-material"} \[229-day LINCL mice treated with 1 mg TPP1 weekly\] and [Movies S8](#mmc8){ref-type="supplementary-material"} and [S9](#mmc9){ref-type="supplementary-material"} \[206-day LINCL mice treated with 2.3 mg TPP1 biweekly\] with [Movie S3](#mmc3){ref-type="supplementary-material"} \[untreated LINCL mouse at 146 days\]). This indicates that IT TPP1 treatment can have differential effects on disease, as some animals that appeared outwardly healthy still died prematurely. At the conclusion of the study (42 weeks), surviving animals treated with 2.3 mg weekly appeared to be healthy. There was no visible tremor; animals were hydrated, feeding, and nesting normally; and they lacked the hunched appearance characteristic of symptomatic LINCL mice. Consistent with these observations, histopathological analysis of brain, kidney, liver, and adrenals from 42-week-old treated animals revealed no notable changes, with the exception of occasional intracellular eosinophilic inclusions in neurons in the brainstem and/or deep cortical regions (data not shown).

Levels of the major storage material in LINCL, subunit c of mitochondrial ATP synthase (SCMAS), were lower in chronic IT-treated animals compared to vehicle-treated controls ([Figure 2](#fig2){ref-type="fig"}A). At 17 weeks, there was a significant accumulation of SCMAS in vehicle-treated LINCL mice (6.1-fold higher than wild-type animals). Levels of SCMAS in treated animals were higher than in wild-type mice but significantly lower than in vehicle-treated animals. Animals were killed 24 hr after the last IT administration, which allowed us to evaluate the efficacy of rhTPP1 delivery to the brain by enzyme assay. While there was animal-to-animal variability as seen previously with IT administration,[@bib12] TPP1 activities in the groups of treated animals were higher than in vehicle-treated LINCL mice ([Figure 2](#fig2){ref-type="fig"}B).

Chronic IT ERT at Late-Stage Disease {#sec2.2}
------------------------------------

Earlier gene therapy studies in LINCL mice demonstrated that efficacy increases the earlier treatment is initiated.[@bib8], [@bib15] However, given that stage of disease may not be the only variable (e.g., viral distribution and, thus, TPP1 expression may be more widespread when treating the smaller brains of younger mice), we have investigated chronic IT ERT in symptomatic animals. A previous gene therapy study in LINCL mice focused on treatment at the earliest stages of detectable disease, i.e., 77 days (11 weeks),[@bib8] but we have instead focused on late-stage disease. At 105 days of age (15 weeks), the cohort of LINCL mice was beginning to die, and there was constant tremor, while locomotor defects were evident from gait analysis ([Figure 1](#fig1){ref-type="fig"}A, stride length at 105 days was diminished from ∼7 to ∼5 cm).

The 15-week LINCL mice were treated with a weekly IT administration of 2.3 mg rhTPP1 ([Figure 3](#fig3){ref-type="fig"}). For most of the animals, IT ERT resulted in a modest increase in lifespan, with median survival increased from 126 to 167 days. However, a subgroup of approximately one-third of the treated late-stage animals was still alive at 42 weeks when the study was terminated.

Stride length of the treated animals continued to decline rapidly after initiating chronic IT ERT ([Figure 3](#fig3){ref-type="fig"}A), similarly to untreated animals ([Figure 1](#fig1){ref-type="fig"}A). This included the subgroup of animals that responded well to treatment in terms of survival. After continuing to decline, locomotor function in long-term survivors then started to improve significantly (see [Figure 3](#fig3){ref-type="fig"}A legend) after 10 weeks of treatment, and it was continuing to improve at the conclusion of the study. At 42 weeks, levels of SCMAS were somewhat elevated compared to control but were lower than younger (17-week) untreated LINCL mice ([Figure 3](#fig3){ref-type="fig"}B).

Distribution of rhTPP1 after IT Administration {#sec2.3}
----------------------------------------------

IT treatment successfully corrected locomotor deficits in LINCL mice, but outwardly healthy animals still died prematurely ([Figure 1](#fig1){ref-type="fig"}). One possible explanation is that IT administration may not effectively deliver rhTPP1 to all regions of the mouse brain. As an example, the cerebellum, which is associated with locomotor function, might be effectively treated because it is readily accessible to the CSF while deeper regions of the brain may not, and subsequent pathology in such untreated regions could result in death. This hypothesis was tested by evaluating the brain distribution of a fluorescent TPP1 derivative delivered via IT administration. In cells where TPP1 was delivered successfully ([Figure 4](#fig4){ref-type="fig"}), its distribution was punctate and cytoplasmic, which is consistent with delivery to the lysosome.

Note that in our previous studies of acute IT administration, we used double-label immunofluoresence microscopy to demonstrate that TPP1 delivered to the brain colocalized with lysosomes containing storage material.[@bib12] Use of chemically labeled fluorescent TPP1 allowed us to clearly visualize the fate of administered TPP1 with minimal non-specific interferences. When the whole brain was imaged in sagittal ([Figure 5](#fig5){ref-type="fig"}A) or coronal section ([Figure 5](#fig5){ref-type="fig"}B), distribution was variable at the anatomic level. We detected strong staining for TPP1 on the surface of the brain in regions proximal to the CSF, including the olfactory bulb and the brainstem, in the ventral regions of anterior olfactory nucleus, ventral striatum, basal forebrain, and hypothalamus. However, there was a gradient of intensity that diminished toward the dorsal surface ([Figure 5](#fig5){ref-type="fig"}C). There was strong staining in what appeared to be blood vessel endothelial cells throughout the brain, which is consistent with endocytosis of some of the administered IT dose that escapes the brain and reaches the plasma.[@bib12] Alternatively, this staining may reflect TPP1 retained within the CSF-accessible perivascular space surrounding blood vessels.

Regional dependence in delivery is illustrated by close examination of individual structures of the brain ([Figure 6](#fig6){ref-type="fig"}). In the cerebellum, there was significant rhTPP1 staining at the outer surface with IT delivery and rhTPP1 delivery to the Purkinje cells of lobes at regions proximal to the surface, e.g., lobe VIII ([Figure 6](#fig6){ref-type="fig"}A). However, Purkinje cells in deeper regions of the cerebellum, e.g., in lobe I, appeared to have undetectable levels of rhTPP1 ([Figure 6](#fig6){ref-type="fig"}B). Delivery to the ventral hypothalamus ([Figure 6](#fig6){ref-type="fig"}C), brainstem ([Figure 6](#fig6){ref-type="fig"}D), anterior cerebral cortex ([Figure 6](#fig6){ref-type="fig"}E), and olfactory bulb ([Figure 6](#fig6){ref-type="fig"}I) was very efficient. However, there was considerably less delivery to the posterior cerebral cortex ([Figure 6](#fig6){ref-type="fig"}F) and deeper regions of the brain, including the hippocampus ([Figure 6](#fig6){ref-type="fig"}G) and thalamus ([Figure 6](#fig6){ref-type="fig"}H). Thus, while chronic treatment might potentially deliver more TPP1 to some of the regions that received little or none in this acute study, TPP1 distribution, when delivered via IT administration, is not uniform.

Discussion {#sec3}
==========

ERT is conceptually a straightforward approach to neurodegenerative lysosomal storage diseases (LSDs), but delivery of proteins to the brain remains problematic. Thus, in proof-of-principle studies of chronic ERT in mouse models, success has been modest in terms of extending survival and improving phenotypes of LSDs. For example, in a recent study,[@bib17] GM2 gangliosidosis mice were treated with chronic ICV administration of a modified β-hexosaminidase A, and this increased median survival by 22% and slowed, but did not prevent, locomotor decline.

In this study, we conducted chronic IT administration, terminating each experiment either at a predetermined endpoint of animal age 42 weeks or when there were only two to three surviving animals in each cohort. While technically challenging, we could conduct up to ∼35 IT injections repeated weekly, but continued administration using this route became difficult due to scarring. We chose IT rather than ICV delivery as previous ERT experiments in LINCL mice[@bib10] demonstrated that implantation of catheters resulted in glial scarring and premature death at 100--110 days. Despite these challenges, we have shown that chronic IT ERT to the brain can be an effective treatment in the LINCL mouse model, extending a median lifespan of 125 days for untreated animals to more than 259 days, with half of the animals surviving at 42 weeks when the study was concluded ([Figure 1](#fig1){ref-type="fig"}A). This represents an increase in lifespan of at least 100%. IT ERT did not prevent premature death in all LINCL mice when initiated at a presymptomatic age. While animals are predosed with cyproheptadine to prevent acute anaphylactic response to rhTPP1 administration, it is possible that there may be differences in immune response in the treated symptomatic animals, with those that die earlier mounting stronger and possibly neutralizing responses. Regardless, chronic IT ERT is similar in efficacy to the most successful gene therapy approaches reported for the LINCL mouse ([Table 1](#tbl1){ref-type="table"}).[@bib8], [@bib15] To our knowledge, this is the most successful demonstration of chronic ERT to the brain of a lysosomal disease mouse model to date.

There are currently no data to indicate whether treatment of late-stage LINCL may or may not provide benefits. In previous studies of ERT in LINCL animal models, treatment was initiated before the onset of disease.[@bib12], [@bib13], [@bib18] In gene therapy studies where LINCL mice were treated at different ages, including at the earliest stage of detectable disease,[@bib8], [@bib15] better results were obtained with earlier treatment. A number of studies evaluated the effects of ERT and gene therapy to symptomatic animal models of other lysosomal diseases.[@bib19], [@bib20], [@bib21], [@bib22], [@bib23] Again, the overall consensus from these studies is that treatment of symptomatic LSD animal models is less effective than that of presymptomatic animals. Treatment of symptomatic animals may correct some biochemical and histopathological features, but, in terms of survival, it is either ineffective or it extends lifespan to a lesser degree than when administered at a presymptomatic age. In terms of locomotor function, late-stage treatment either has no effect or it slows, but does not stop, decline. Thus, a major goal of this study was to determine whether chronic treatment might benefit symptomatic, late-stage LINCL mice.

We found that in about two-thirds of late-stage mice (15 weeks old), IT ERT extended survival only modestly. However, an unexpected finding was that, in the remaining third, lifespan was extended to more than 42 weeks, at which point the study was concluded ([Figure 3](#fig3){ref-type="fig"}). This extension in survival was equivalent to that observed in mice treated before disease onset. It is not clear why only a subset of the symptomatic animals responded well to treatment, but, as discussed earlier, this could reflect differences in immune response. However, there is a window in which the LINCL mice die (100--150 days). It is possible that the ones that responded well to treatment are the animals that would have naturally died toward the end of this window. If so, this may indicate that there is a committed point in the progression of the disease at which treatment, no matter how effective in terms of TPP1 amounts and distribution, will have a modest or no effect on survival.

In late-stage animals that responded well to treatment, locomotor function measured by gait analysis continued to decrease after treatment was initiated, to or below the level of untreated LINCL mice shortly before death. However, as they survived beyond this point, locomotor function then began to show a steady and significant improvement. While previous studies have shown that treatment can prevent or slow decline in locomotor function when administered to presymptomatic or symptomatic lysosomal disease mouse models,[@bib8], [@bib15], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] our data indicate that successful treatment has the potential to actually rescue locomotor function in animals that are already compromised. This establishes an important precedent that at least one phenotype of a neurological lysosomal disease can potentially be reversed with effective treatment. The underlying basis for phenotypic rescue remains unclear. It is possible that effective delivery of rhTPP1 corrects neurons that are alive but compromised and not functioning correctly. Alternatively, this may reflect plasticity of the brain, with compensatory changes resulting in improved locomotor function as further neurodegeneration is halted. Regardless, the fact that some of the highly symptomatic animals survived with treatment and that they showed a partial rescue of a complex phenotype of disease potentially has implications for the treatment of LINCL patients.

IT ERT can effectively ameliorate locomotor deficits and maintain SCMAS at levels observed in wild-type animals without preventing premature death of the LINCL mice. One possibility is that death may result from peripheral defects, but, with extensive delivery of IT-administered rhTPP1 to visceral organs in addition to the brain,[@bib12] this appears unlikely. Another possibility is that effective delivery of rhTPP1 to the spinal cord via intrathecal delivery, as has been observed in a previous acute IT ERT study,[@bib24] may provide locomotor benefits without preventing death. However, perhaps the likeliest scenario, which is supported by our acute distribution experiments, is that death results from pathology in deeper regions of the brain where rhTPP1 appears to be less efficiently delivered by IT administration. This explanation is consistent with several previous studies. rhTPP1 was administered to an LINCL dog model and wild-type controls,[@bib25] and, in the former, extremely high rhTPP1 activity was detected in the hypothalamus and cerebellum (∼12-fold higher than wild-type), while low or undetectable levels of rhTPP1 were delivered to deep regions, including the thalamus (0.4-fold of wild-type). Cynomolgus monkeys were treated with IT administration of rhTPP1,[@bib26] and, again, levels in cerebellum were high (∼12-fold higher than wild-type) and low in the thalamus (∼0.5-fold of wild-type). This uneven distribution may reflect the fact that the CSF-brain interface is anatomically limited, requiring significant diffusion of a therapeutic for complete coverage.[@bib27] In addition, efficient delivery of TPP1 to the ventral areas by IT administration in the mouse may reflect the flow pattern of CSF throughout the brain, with outflow from the ventricles essentially pushing the IT dose under or around the brain. ICV administration, which is the approach used in the recent clinical trial of rhTPP1 for LINCL (ClinicalTrials.gov: [NCT01907087](ctgov:NCT01907087){#intref0040}), provides a better distribution of rhTPP1 throughout the monkey brain,[@bib26] but rhTPP1 is still delivered with variable efficiency to different regions. It is worth noting that TPP1 deficiency is associated with cerebellar atrophy in both spinocerebellar ataxia 7[@bib28] and LINCL (reviewed in Anderson et al.[@bib29]), and loss of cerebellar neurons occurs in the mouse model.[@bib6] The fact that rhTPP1 is delivered by IT ERT to the cerebellum, at least to outer layers ([Figure 6](#fig6){ref-type="fig"}), may explain why locomotor function is preserved with treatment.

Two major conclusions from this study may have implications for the treatment of LINCL and possibly related LSDs. First, IT ERT (and presumably other methods that restore TPP1 to the brain) at symptomatic late-stage disease has the potential to significantly extend lifespan and at least partially correct existing locomotor deficits. Second, while IT ERT prevents locomotor decline when initiated presymptomatically, it does not necessarily prevent premature death. While ataxia is the only locomotor parameter that we evaluated in the mouse model, this is a precedent that raises specific concerns when individual phenotypes of disease are used as part of a measure of disease progression.[@bib30], [@bib31] It is possible that other measurable parameters, e.g., vision and speech, also respond to treatment in ways that are not necessarily indicative of survival. This should be borne in mind when using tests for discrete neurological functions to monitor overall disease progression when evaluating the efficacy of ERT to the brain.

Materials and Methods {#sec4}
=====================

Materials {#sec4.1}
---------

The rhTPP1 proenzyme in artificial CSF (aCSF) at a concentration of 29 mg/mL was generously provided by Biomarin, and it was used directly for IT injection. Note that our earlier prediction[@bib12] for a solubility limit for TPP1 of ∼20 mg/mL was an underestimate. Fluorescently labeled rhTPP1 was generated by reaction with Alexa Fluor 647 NHS Ester (Thermo Fisher Scientific), and salts and unreacted dye were removed by buffer exchange using PD10 columns. Labeling efficiency was 0.7 mol dye/mol TPP1 based on absorbance using molar extinction coefficients of ε280 = 82,195 for TPP1 and ε280 = 7,170 and ε467 = 239,000 for Alexa Fluor 647.

Animals {#sec4.2}
-------

Animals were maintained and used following protocols approved by the Rutgers University and Robert Wood Johnson Medical School Institutional Animal Care and Use Committee ("Preclinical evaluation of therapy in an animal model for LINCL," protocol I09-0274-4). Male and female LINCL mice were in a C57BL/6 background and genotyped as described previously.[@bib6] The rhTPP1 was administered by IT injection essentially as described,[@bib12] except animals were pretreated by intraperitoneal administration of 5 mg/kg cyproheptadine from the second or third dose onward to prevent anaphylactic response. In brief, animals were anesthetized with isoflurane using an anesthesia inhalation system (VetEquip), and 80 μL TPP1 solution was administered at a rate of 10 μL/min using a syringe pump (New Era Pump Systems). Mice were housed singly from 6 weeks old (asymptomatic animals) or 9 weeks old (symptomatic animals) and gently handled to avoid fatal startle seizures.[@bib6] Locomotor function was measured by biweekly gait analysis.[@bib32] For analysis of TPP1 uptake, animals were IT-injected with 1 mg fluorescent TPP1, killed, perfused with saline, and brains were dissected sagitally or coronally into two segments. One half was frozen for enzyme activity and other biochemical analyses, and the other, along with liver, kidney, and adrenals, was fixed for histopathology as described.[@bib14]

Microscopy {#sec4.3}
----------

For the determination of fluorescent TPP1 distribution, animals were perfused with saline and then perfusion-fixed with 4% paraformaldehyde in PBS (PFA/PBS). Brains were excised, fixed for 48 hr in 4% PFA/PBS, and then transferred to 30% sucrose/PBS at 4°C until they sunk. After embedding in Richard Allen Scientific NEG-50 (Thermo Fisher Scientific), 20-μm sections were cut using a Leica CM1900 cryostat (Leica Biosystems) and mounted using Fluoro-Gel II with DAPI (Electron Microscopy Sciences). Whole-slide images were acquired using an Olympus VS120 whole-slide scanner equipped with an Olympus XM10 cooled monochrome 14-bit camera.

Experimental Design for Survival and Gait Studies {#sec4.4}
-------------------------------------------------

Survival data from various treatments were compared with historical data from 1,560 untreated C57BL/6 LINCL mice that were acquired over many years of maintaining this model. In the first survival study (2.3 mg TPP1 administered weekly from 6 weeks of age), cohorts were treated either with rhTPP1 or with vehicle alone. Given that survival of vehicle-treated LINCL mice was equivalent to that of historical control untreated animals, this group was not included for subsequent survival studies of LINCL mice treated with other regimens.

Gait analyses were initially conducted on cohorts of wild-type and LINCL mice and subsequently on the cohort administered 2.3 mg TPP1 weekly from 6 weeks of age and accompanying vehicle controls. Given that gait measurements of the vehicle-treated LINCL mice were indistinguishable from the previous cohort of untreated LINCL mice, we excluded this control group from subsequent treatment groups. In plotting survival curves, data from the initial wild-type and untreated LINCL cohorts are plotted with all treatment groups for reference.

SCMAS Immunoblotting {#sec4.5}
--------------------

Mouse brain samples were homogenized in 1:50 volumes (w/v) of 0.15 M NaCl/0.1% Triton X-100 using a Polytron tissue homogenizer (Kinematica). One hundred microliters of each homogenate (∼1.5 mg protein/mL) were centrifuged at 14,000 × *g* for 30 min to separate the insoluble storage material containing SCMAS from normal mitochondrial SCMAS, as described previously.[@bib14] Pellets were resuspended in 100 μL homogenization buffer and recentrifuged. The pellet was dissolved in reducing lithium dodecyl sulfate PAGE buffer and analyzed by immunoblotting as described.[@bib12]

Statistical Analyses {#sec4.6}
--------------------

Statistical analyses were conducted using Prism 5.03 (GraphPad) and R-3.3.[@bib33] For comparison of SCMAS levels in vehicle-treated LINCL mice with other treatment groups ([Figure 2](#fig2){ref-type="fig"}A), measurements were log-transformed according to y = log(x) and a linear model was fitted, with the transformed variables as the response variable and the groups as predictors. The vehicle group was used as the reference, and all other parameter estimates represent differences between the respective groups and the reference group. Standard analysis of the residuals was performed to verify that the statistical assumptions underlying the linear model were met.[@bib34] For comparison of TPP1 activities in vehicle-treated LINCL mice with other treatment groups ([Figure 2](#fig2){ref-type="fig"}B), the same procedure was used except that measurements were log-transformed according to y = log(x + 0.15).
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![Chronic IT Enzyme Replacement Therapy of Asymptomatic Animals\
Treatment was initiated at 42 days of age. Dashed lines in survival curves are SE; gait error bars are SEM. Treatment groups were compared with untreated animals using log-rank (Mantel-Cox) tests. (A) Survival of animals treated weekly with 2.3 mg rhTPP1 (n = 13 animals) was significantly increased (p \< 0.0001) from vehicle (aCSF) alone (n = 10) or untreated animals. (B) Survival of animals treated with a weekly administration of 1 mg rhTPP1 (n = 12) was significantly (p \< 0.0001) increased. (C) Survival of animals treated with a biweekly administration of 2.3 mg rhTPP1 (n = 12) was significantly (p \< 0.0001) increased.](gr1){#fig1}

![Storage Material and TPP1 Activity\
Significance of changes in SCMAS and TPP1 activity relative to vehicle-treated LINCL mice was calculated by fitting data to a linear model, as described in the [Materials and Methods](#sec4){ref-type="sec"}. (A) Detection of SCMAS in isolated storage material by immunoblotting in animals treated with a weekly administration of 2.3 mg rhTPP1 and controls. Samples from 16-week-old wild-type and LINCL animals are shown as reference standards. Analysis of older wild-type animals indicated that there were no detectable age-related changes in SCMAS levels (data not shown). Relative SCMAS levels obtained from multiple loadings (4 and 8 μg protein equivalents of original homogenate) were normalized to average signal obtained from 17-week-old wild-type animals; error bars show SEM (n = 3 per treatment group). Significance of change compared to vehicle-treated LINCL mice, \*p \< 0.05/3 (i.e., 0.05 after Bonferroni correction for three individual comparisons). (B) TPP1 activities measured in brain, 24 hours after administration of the final dose. Data are expressed relative to average TPP1 activity in 17-week-old wild-type animals. Significance of change compared to vehicle treated animals, \*p \< 0.05/7 (i.e., 0.05 after Bonferroni correction for seven individual comparisons).](gr2){#fig2}

![IT ERT in Late-Stage Disease\
Weekly administration of 2.3 mg rhTPP1 was initiated at 105 days of age (n = 12 animals). (A) Survival and gait analysis data. Dashed lines in survival plot indicate SE. Survival of treated animals was significantly increased compared to untreated animals (p \< 0.0001, log-rank \[Mantel-Cox\] test). Stride length is plotted for each individual animal to demonstrate variability. Linear regression of stride length data from 175 to 287 days indicates that the increase in stride length observed after 175 days is highly significant (hind gait, slope = 0.015 ± 0.002, p \< 0.0001; front gait, slope = 0.013 ± 0.002, p \< 0.0001). (B) SCMAS in LINCL mice at 42 weeks of age. The ∼16-week-old wild-type and LINCL animals are shown as reference standards.](gr3){#fig3}

![Intracellular Distribution of Fluorescent TPP1\
Wild-type mice were treated with 1 mg Alexa-647-labeled rhTPP1 via IT administration. Then 18 hr later, animals were killed, and brains were analyzed by confocal microscopy to measure the distribution of fluorescently labeled TPP1. Images were captured using a 40× objective. Blue, DAPI; red, Alexa-647 rhTPP1. Note that images were chosen for each brain region to illustrate intracellular distribution and are not meant to be representative of each respective brain region as a whole.](gr4){#fig4}

![Distribution of Fluorescent TPP1\
(A--C) Wild-type mice (n = 3) were treated with Alexa-647-labeled rhTPP1 via IT administration. Then 18 hr later, animals were killed, and brains were analyzed by confocal microscopy to measure the distribution of fluorescently labeled rhTPP1. (A) Sagittal section, (B) coronal section, and (C) quantitation of relative fluorescent rhTPP1 signal through a dorsal-ventral section are shown (n = 3 animals, error bars depict SEM). Images were captured using a 20× objective. Blue, DAPI; red, Alexa-647 rhTPP1.](gr5){#fig5}

![Distribution of Fluorescent rhTPP1 in Defined Brain Regions in Sagittal Section\
See [Figure 5](#fig5){ref-type="fig"} for details. Color ranges in all panels are identical. (A) Cerebellum, lobe VIII; (B) cerebellum, lobe I; (C) hypothalamus; (D) brainstem; (E) anterior cerebral cortex; (F) posterior cerebral cortex; (G) hippocampus; (H) thalamus; and (I) olfactory bulb are shown. Scale bars represent 100 μm except in (G) (200 μm) and (I) (500 μm). Blue, DAPI; red, Alexa-647-labeled rhTPP1.](gr6){#fig6}

###### 

Summary of Survival Data from Gene Therapy and Enzyme Replacement Studies Conducted in LINCL Mice

  Study                                            Treatment Method                                            Strain                Treatment Age (days)   Median Survival (days)   Maximum Survival (days)
  ------------------------------------------------ ----------------------------------------------------------- --------------------- ---------------------- ------------------------ -------------------------
  Sleat et al.[@bib6]                              none                                                        mixed C57BL/6:129Sv                          138                      ∼170
  none                                             129Sv                                                                             164                    ∼185                     
  Cabrera-Salazar et al.[@bib8]                    none                                                        NR                                           151                      ∼175
  gene therapy                                     NR                                                          28                    \>330                  \>330                    
  gene therapy                                     NR                                                          77                    216                    ∼230                     
  Sondhi et al.[@bib15]                            none                                                        C57BL/6                                      121                      133
  gene therapy                                     C57BL/6                                                     2                     376                    400                      
  gene therapy                                     C57BL/6                                                     21                    277                    370                      
  gene therapy                                     C57BL/6                                                     49                    168                    350                      
  Xu et al.[@bib12]                                none                                                        C57BL/6                                      125                      170
  1.2 mg rhTPP1, intrathecal, acute, replicate 1   C57BL/6                                                     28                    163                    190                      
  1.2 mg rhTPP1, intrathecal, acute, replicate 2   C57BL/6                                                     28                    164                    180                      
  1.2 mg rhTPP1, intrathecal, acute, replicate 3   C57BL/6                                                     28                    155                    168                      
  0.038 mg rhTPP1, intrathecal, acute              C57BL/6                                                     28                    135                    160                      
  0.12 mg rhTPP1, intrathecal, acute               C57BL/6                                                     28                    130                    145                      
  0.38 mg rhTPP1, intrathecal, acute               C57BL/6                                                     28                    145                    145                      
  Meng et al.[@bib14]                              acute i.v. administration of rhTPP1 with peptide mediator   C57BL/6               42                     156                      190
  Current study                                    none                                                        C57BL/6                                      126                      175
  2.3 mg rhTPP1, intrathecal, chronic, weekly      C57BL/6                                                     initiated at 42       \>259                  \>300                    
  1.0 mg rhTPP1, intrathecal, chronic, weekly      C57BL/6                                                     initiated at 42       220                    223                      
  2.3 mg rhTPP1, intrathecal, chronic, biweekly    C57BL/6                                                     initiated at 42       201                    203                      
  2.3 mg rhTPP1, intrathecal, chronic, weekly      C57BL/6                                                     initiated at 105      167                    \>300                    

NR, not reported.
